Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1141255

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Non-surgical Cosmetic Procedures: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what legal duties govern the administering of dermal fillers to people under the age of 18 by non-regulated practitioners.
	tabling member constituency	North Durham
	tabling member printed	Mr Kevan Jones
	uin	280927
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Currently there are no restrictions that limit the administration of dermal fillers on young people under the age of 18 years old.</p><p>The Department is exploring options to introduce age restrictions on access to cosmetic procedures, bringing them in line with legislation on tattoos, teeth whitening and the use of sunbeds. From May 2020 all dermal fillers, irrespective of their composition and intended use, will be regulated as medical devices under Annex XVI of the Medical Device Regulations (EU 2017/745). The new Regulations will significantly improve the quality and safety of dermal fillers.</p><p>The Government is committed to improving the safety of cosmetic procedures through better training for practitioners, and clear information so that people can make informed decisions about their care. The growth in non-surgical treatments increases the need for consumer protection and we are currently working with stakeholders to strengthen the regulation of cosmetic procedures.</p><p>We urge anyone seeking a cosmetic procedure to take the time to find a reputable, insured and appropriately qualified practitioner who is either subject to statutory regulation or on a voluntary register accredited by the Professional Standards Authority.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:32:36 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1438 label Biography information for Mr Kevan Jones

1138547

	registered interest
	date	11/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Obesity: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the prevalence of obesity amongst children with special needs.
	tabling member printed	Lord Brooke of Alverthorpe
	uin	HL17105
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>There has been no central assessment of the prevalence of obesity amongst children with special needs.</p><p> </p><p>We published the second chapter of our world-leading childhood obesity plan in June 2018. This builds on the real progress we have made since the publication of chapter one in 2016, particularly in reformulation of the products our children eat and drink most. Measures in both chapters of our plan will help reduce obesity in people of all ages and abilities including those with special needs.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17106 question first answered 25/07/2019 16:33:21 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3335 label Biography information for Lord Brooke of Alverthorpe

1138548

	registered interest
	date	11/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Obesity: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what action, if any, they are taking to reduce rates of obesity amongst 12–16 year olds with special needs.
	tabling member printed	Lord Brooke of Alverthorpe
	uin	HL17106
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>There has been no central assessment of the prevalence of obesity amongst children with special needs.</p><p> </p><p>We published the second chapter of our world-leading childhood obesity plan in June 2018. This builds on the real progress we have made since the publication of chapter one in 2016, particularly in reformulation of the products our children eat and drink most. Measures in both chapters of our plan will help reduce obesity in people of all ages and abilities including those with special needs.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17105 question first answered 25/07/2019 16:33:21 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3335 label Biography information for Lord Brooke of Alverthorpe

1141380

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	MMR Vaccine: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	280998
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:35:38 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1141381

	registered interest
	date	23/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	MMR Vaccine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine.
	tabling member constituency	Gravesham
	tabling member printed	Adam Holloway
	uin	280999
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:38:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	1522 label Biography information for Adam Holloway

1141957

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Breast Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what are the drugs approved by NICE to treat HER2+ breast cancer; and what assessment they have made of the efficacy of such drugs.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17501
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17502 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1141958

	registered interest
	date	24/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pertuzumab
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what advice they provide to clinicians for the use of Pertuzumab rather than Herceptin for the treatment of HER2+ breast cancer.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL17502
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for making recommendations for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE has recommended the following drugs for the treatment of HER2-positive breast cancer: trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab (Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta) for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta) for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners are legally required to fund drugs recommended in NICE technology appraisal guidance. It is for clinicians to decide on the most appropriate treatment for an individual patient based on their clinical judgement and in discussion with the patient.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17501 question first answered 25/07/2019 16:45:03 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1139047

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accident and Emergency Departments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the effect of late licensing on the workload of accident and emergency departments in hospitals.
	tabling member printed	Lord Browne of Belmont
	uin	HL17132
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>No such assessment has been made.</p> answering member printed Baroness Blackwood of North Oxford question first answered 25/07/2019 16:45:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3801 label Biography information for Lord Browne of Belmont

1140467

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Psychiatric Hospitals: Children and Young People
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government on what dates each of the registered Child and Adolescent Mental Health Tier 4 inpatient services were last inspected; and what is the schedule for future inspections for each service.
	tabling member printed	Baroness Jolly
	uin	HL17300
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>The Care Quality Commission (CQC) has provided the following response.</p><p>The dates each of the registered Child and Adolescent Mental Health Tier 4 inpatient services were last inspected are attached, due to the size of the data.</p><p>The CQC carry out either comprehensive or focused inspections. For National Health Service trusts, these inspections will usually be unannounced.</p><p>In a few instances, where there are very good reasons, the CQC may let a service know it is coming. For example, the CQC may contact a trust to make sure senior management are present to answer its questions.</p><p>To enable the CQC to observe normal practice in a service, it has introduced more unannounced inspections as part of its comprehensive inspection methodology.</p><p>Because the CQC requests information from providers beforehand, it will carry out the inspection within three months of the provider submitting its provider information request. However, the CQC will not announce the day on which it intends to inspect.</p> answering member printed Baroness Blackwood of North Oxford question first answered 25/07/2019 16:45:37 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name HL17300 table formatted.docx title CAMHS Tier 4 inpatient inspections
	tabling member	4203 label Biography information for Baroness Jolly

1140481

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Nurses
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many nurses were employed by the NHS in England in each year since 2004.
	tabling member printed	Baroness McDonagh
	uin	HL17314
	answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>NHS Digital publishes Hospital and Community Health Services (HCHS) workforce statistics for England. These include staff working in hospital trusts and clinical commissioning groups (CCGs), but not staff working in primary care, local authorities or other providers.</p><p>The following table shows the number of nurses and health visitors and midwives who work in National Health Service trusts and CCGs in England, as at September each year since 2004 and March 2019 (latest available data), full time equivalent. Nurses and health visitors are recorded together so we are unable to provide data solely for nurses.</p><p><strong> </strong></p><table><tbody><tr><td><p> </p></td><td><p>Nurses and health visitors in NHS Trusts and CCGs</p></td><td><p>Midwives in NHS Trusts and CCGS</p></td></tr><tr><td><p>September 2004</p></td><td><p>268,704</p></td><td><p>18,137</p></td></tr><tr><td><p>September 2005</p></td><td><p>276,086</p></td><td><p>18,326</p></td></tr><tr><td><p>September 2006</p></td><td><p>277,387</p></td><td><p>18,380</p></td></tr><tr><td><p>September 2007</p></td><td><p>275,211</p></td><td><p>18,751</p></td></tr><tr><td><p>September 2008</p></td><td><p>281,021</p></td><td><p>18,896</p></td></tr><tr><td><p>September 2009</p></td><td><p>278,470</p></td><td><p>18,959</p></td></tr><tr><td><p>September 2010</p></td><td><p>279,883</p></td><td><p>19,487</p></td></tr><tr><td><p>September 2011</p></td><td><p>277,047</p></td><td><p>19,878</p></td></tr><tr><td><p>September 2012</p></td><td><p>271,407</p></td><td><p>20,214</p></td></tr><tr><td><p>September 2013</p></td><td><p>274,627</p></td><td><p>20,537</p></td></tr><tr><td><p>September 2014</p></td><td><p>278,981</p></td><td><p>20,838</p></td></tr><tr><td><p>September 2015</p></td><td><p>281,474</p></td><td><p>20,934</p></td></tr><tr><td><p>September 2016</p></td><td><p>284,288</p></td><td><p>21,038</p></td></tr><tr><td><p>September 2017</p></td><td><p>283,853</p></td><td><p>21,206</p></td></tr><tr><td><p>September 2018</p></td><td><p>285,674</p></td><td><p>21,323</p></td></tr><tr><td><p>March 2019</p></td><td><p>290,010</p></td><td><p>21,870</p></td></tr></tbody></table><p><em>Sources: Non-Medical Workforce Census, NHS Digital workforce statistics </em></p><p>The following table shows the number of nursing students commissioned by the Department/Health Education England (HEE) in each year since 2004 and the number of acceptances to nursing degree courses via the Universities and Colleges Admissions Service (UCAS). Following student finance reform, students starting courses after August 2017 were no longer directly commissioned by HEE.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Nursing students commissioned by the Department/HEE</p></td><td><p>Number of acceptances to nursing degree courses via UCAS</p></td></tr><tr><td><p>2004/05</p></td><td><p>22,933</p></td><td><p>N/A</p></td></tr><tr><td><p>2005/06</p></td><td><p>20,183</p></td><td><p>N/A</p></td></tr><tr><td><p>2006/07</p></td><td><p>20,917</p></td><td><p>N/A</p></td></tr><tr><td><p>2007/08</p></td><td><p>19,147</p></td><td><p>N/A</p></td></tr><tr><td><p>2008/09</p></td><td><p>20,323</p></td><td><p>N/A</p></td></tr><tr><td><p>2009/10</p></td><td><p>20,366</p></td><td><p>N/A</p></td></tr><tr><td><p>2010/11</p></td><td><p>19,908</p></td><td><p>N/A</p></td></tr><tr><td><p>2011/12</p></td><td><p>17,633</p></td><td><p>N/A</p></td></tr><tr><td><p>2012/13</p></td><td><p>17,115</p></td><td><p>N/A</p></td></tr><tr><td><p>2013/14</p></td><td><p>17,568</p></td><td><p>N/A</p></td></tr><tr><td><p>2014/15</p></td><td><p>19,147</p></td><td><p>N/A</p></td></tr><tr><td><p>2015/16</p></td><td><p>19,951</p></td><td><p>N/A</p></td></tr><tr><td><p>2016/17</p></td><td><p>20,888</p></td><td><p>N/A</p></td></tr><tr><td><p>2017/18</p></td><td><p>N/A</p></td><td><p>19,515</p></td></tr><tr><td><p>2018/19</p></td><td><p>N/A</p></td><td><p>19,035</p></td></tr></tbody></table><p><em>Sources: HEE-Education Commissioning Dataset, UCAS end of cycle data 2018</em></p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL17315 HL17316 question first answered 25/07/2019 16:45:56 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	3701 label Biography information for Baroness McDonagh